5-Amino-1MQ And NNMT Inhibition: Lean Fat Loss Explained
The enzyme that steals NAD+ from your fat cells. The compound that blocks it. And the surprisingly specific way this might help with sarcopenic obesity.
Quick read: 5-Amino-1MQ is a small molecule that inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that consumes NAD+ precursors. Blocking NNMT increases intracellular NAD+, promotes fat oxidation, and appears to spare lean mass. Strong animal data. No FDA-approved human version. Research-chemical availability only.
Meet NNMT
NNMT is an enzyme that methylates nicotinamide (a form of vitamin B3) and burns through S-adenosylmethionine (SAM) in the process. Every time NNMT fires, you:
- Lose one nicotinamide → one fewer NAD+ precursor
- Lose one SAM → one fewer methyl donor for other reactions
- Produce 1-methylnicotinamide (MNA) as a byproduct
In moderation, this is fine — NNMT is part of normal metabolism. But in fat tissue of obese individuals, NNMT is dramatically overexpressed. It's been found elevated 2–4x in visceral and subcutaneous adipose tissue in obesity.
Why this matters: high NNMT activity in adipose tissue depletes local NAD+, impairs cellular energy metabolism, and promotes further fat storage via reduced lipolysis. It's a self-reinforcing loop.
The NNMT inhibitor approach
If NNMT is consuming NAD+ in fat cells and promoting fat storage, what happens if you block NNMT?
That's the research question. 5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective NNMT inhibitor developed at the University of Texas and described by Neelakantan et al. in 2017. It:
- Binds NNMT's active site directly
- Prevents methylation of nicotinamide
- Increases intracellular NAD+ in treated cells
- Promotes fat oxidation in adipocytes
- Is orally bioavailable (a big advantage)
The landmark animal study
Kraus et al., 2014 (Washington University):
- Obese mice with NNMT expression knocked down in fat tissue
- Result: significant fat loss without calorie restriction
- Lean mass was preserved or increased
- Muscle protein synthesis improved
- Insulin sensitivity improved
This was the first demonstration that NNMT is a metabolic lever — suppressing it changes fat cell energy balance and body composition without calorie manipulation.
Follow-up studies with 5-Amino-1MQ specifically replicated these findings using pharmacological (rather than genetic) inhibition.
The muscle-preservation angle
One thing that makes 5-Amino-1MQ unusually interesting: it appears to preserve lean mass.
Most weight-loss interventions (calorie restriction, GLP-1s) produce ~25–40% of weight lost as muscle. 5-Amino-1MQ in mouse models produces:
- Fat loss ~10–15%
- Lean mass change minimal or positive
- Net body composition improvement proportionally much greater than simple weight reduction
The mechanism: increased intracellular NAD+ supports muscle protein synthesis, while fat cells specifically show increased fat oxidation. Different tissue responses to the same intervention.
This makes 5-Amino-1MQ particularly interesting for sarcopenic obesity — the combination of low muscle mass and high body fat that's common in older adults and associated with poor health outcomes.
What the research does and doesn't show
Strong evidence (preclinical):
- Fat loss in obese animals without calorie restriction
- Lean mass preservation
- Improved insulin sensitivity
- Reduced hepatic lipogenesis
- Restored muscle protein synthesis in sarcopenic mice
Weak evidence:
- Human translation (very limited clinical data)
- Long-term effects (most animal studies <6 months)
- Effects in non-obese populations
- Combination with other interventions
No evidence:
- Controlled human trials in healthy adults
- Long-term (>2 year) safety in humans
- Effects on cardiovascular outcomes
Typical research protocols
Reported research dosing ranges:
- 150 mg orally daily (most common cited protocol)
- Some protocols go 50–300 mg/day
- Twice-daily dosing for better plasma steady-state
- Cycles of 8–12 weeks — long-term continuous use not yet characterized
Formulation: Oral capsules, often combined with niacin or B-vitamins to support NAD+ synthesis pathways.
Safety profile
Known in animals:
- No acute toxicity at 10x typical doses
- No obvious effect on hepatic function
- No cardiovascular signals in available studies
Unknown in humans:
- Long-term effects
- Drug interactions
- Effects on reproductive/endocrine systems
- Cumulative NNMT blockade effects (NNMT has physiological functions; sustained inhibition may have consequences not captured in short studies)
Who might benefit
Based on the preclinical profile, 5-Amino-1MQ's research interest centers on:
1. Sarcopenic obesity — the most specific potential indication. Combination of muscle-preserving and fat-reducing mechanisms.
2. Age-related metabolic decline — NNMT activity increases with age, paralleling NAD+ decline. Inhibiting it addresses an age-related dysregulation.
3. Post-GLP-1 maintenance — after aggressive weight loss on GLP-1s, keeping the weight off while rebuilding muscle is difficult. 5-Amino-1MQ's profile is at least theoretically well-suited to this use case.
4. Type 2 diabetes research — insulin sensitivity improvements in animal studies suggest metabolic applications.
What's new in 2026
- First human dose-finding studies are beginning in 2026 — small-scale, primarily in sarcopenic obesity populations
- Commercial development is happening through at least two biotech startups pursuing NNMT as a drug target
- Supplement-grade versions (non-pharmaceutical, "research chemical" status) are widely available
- No FDA-approved pharmaceutical version expected before 2028 at earliest
Bottom line
5-Amino-1MQ sits in an interesting risk/reward position:
- Mechanism: Well-characterized, targeted, biologically reasonable
- Animal data: Strong, multi-lab replicated
- Human data: Early, limited
- Supplier quality: Variable; this is a small molecule sold by peptide suppliers despite not being a peptide
- Long-term safety: Unknown
For researchers interested in metabolic interventions beyond GLP-1s, it's worth watching. For patients looking for proven weight-loss therapy, it isn't ready yet.
5-Amino-1MQ is not a peptide (it's a small molecule), not FDA-approved, and not characterized for human safety at scale. Use is research-only and carries unknown risks.
Read next: 5-Amino-1MQ peptide profile, or MOTS-c profile for another metabolic peptide.
PEPGAINS RESEARCH
Independent peptide research, read by 8,400 researchers. Every claim cited, every affiliate disclosed.